Los Angeles Capital Management LLC lowered its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 40.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 73,117 shares of the biopharmaceutical company's stock after selling 50,284 shares during the quarter. Los Angeles Capital Management LLC's holdings in TG Therapeutics were worth $2,201,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. grew its position in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 849 shares during the period. Synergy Asset Management LLC purchased a new stake in TG Therapeutics in the 4th quarter valued at about $75,000. GAMMA Investing LLC increased its stake in shares of TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock valued at $77,000 after acquiring an additional 2,171 shares during the last quarter. KBC Group NV lifted its holdings in shares of TG Therapeutics by 30.5% during the 3rd quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company's stock worth $109,000 after acquiring an additional 1,092 shares during the period. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of TG Therapeutics in the third quarter worth approximately $111,000. 58.58% of the stock is owned by hedge funds and other institutional investors.
TG Therapeutics Stock Up 14.4 %
Shares of TGTX traded up $4.33 during midday trading on Monday, reaching $34.42. 12,628,827 shares of the company were exchanged, compared to its average volume of 2,402,081. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 1-year low of $12.93 and a 1-year high of $36.84. The company has a market cap of $5.36 billion, a price-to-earnings ratio of -344.17 and a beta of 2.26. The stock has a 50-day moving average price of $30.75 and a 200-day moving average price of $28.14.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.06. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. Research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.
Insider Transactions at TG Therapeutics
In related news, CFO Sean A. Power sold 11,337 shares of the business's stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the transaction, the chief financial officer now owns 670,632 shares in the company, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 10.50% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on TGTX. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Wednesday, January 15th. JPMorgan Chase & Co. lifted their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a report on Monday, November 25th. The Goldman Sachs Group upped their price target on TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Finally, StockNews.com lowered TG Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, January 31st. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $40.67.
Get Our Latest Research Report on TGTX
TG Therapeutics Company Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Read More
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
